Access Oncology and Zentaris AG, a subsidiary of Degussa AG entered into licensing and co-development agreement for Zentaris’ perifosine for the treatment of tumors. The deal could be worth up to US$30 M to Zentaris if specific milestones and sales targets are met along with US, Canadian and Mexican rights for the drug.